certificate of analysis is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-14. Numbers and descriptions here follow the published literature rather than marketing material.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid as supplied |
| Water solubility | Soluble | Dissolves in aqueous media |
| Typical storage temperature | -20 °C | Dry powder, desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity from peak area; mass for identity |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies by supplier and catalogue |
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
==== State actors ==== Algeria: Algeria strongly condemned the Israeli attack on Syria, calling it a flagrant violation of sovereignty. Bahrain: Bahrain welcomed the Syrian government's announcement of a ceasefire in Suwayda province, saying the measure contributes to improving security, stability and preserving civil peace. China: China emphasized that Syria's sovereignty and territorial integrity must be respected. Egypt: Egypt condemned the repetitive attacks on Syria as a "violation" of the sovereignty of the country and a "breach of international law". France: France called for an end to "abuses targeting civilians" in Suwayda and a "immediate cessation of clashes". Germany: Germany threatened to suspend its support for the Syrian transitional government following the events in Suwayda. Iran: Iran expressed strong condemnation of the attacks by Israel on Syria and made concerns on the clashes in Suwayda. Iraq: Iraq expressed its deep concern over the escalating tensions in Syria and strongly condemned Israel's repeated military interventions, calling them flagrant violations of sovereignty. Japan: Japan calls for respecting Syria's sovereignty and territorial integrity. Lebanon: Lebanon condemns Israeli attacks on Syria and urges international community to assume its responsibilities, the Lebanese politician, Walid Jumblatt, warned against "the plots of Israel" and accused Netanyahu of attempting to create sectarian division and chaos in Syria. Russia: Russia condemned the Israeli strikes in Syria, calling it a violation of Syria's sovereignty.
From its incorporation in 2003 until 2018, Holmes was the company's chief executive officer. She recruited Channing Robertson, a chemical-engineering professor at Stanford, to be a technical advisor and the company's first board member during its early years. Holmes's then-boyfriend Sunny Balwani, a software engineer whom Holmes had met during high school, joined the company as its president and chief operating officer in 2009. In July 2011, Holmes was introduced to former U.S. Secretary of State George Shultz, who joined the Theranos board of directors that month. Over the next three years, Shultz helped to introduce almost all the outside directors on the "all-star board", which included William Perry (former U.S. Secretary of Defense), Henry Kissinger (former U.S. Secretary of State), Sam Nunn (former U.S. Senator), Bill Frist (former U.S. Senator, senate majority leader and heart-transplant surgeon), Gary Roughead (Admiral, USN, retired), Jim Mattis (General, USMC), Richard Kovacevich (former Wells Fargo Chairman and CEO) and Riley P. Bechtel (chairman of the board and former CEO at Bechtel Group). The board was criticized for consisting "mainly of directors with diplomatic or military backgrounds". In April 2016, Theranos announced its medical advisory board, which included past presidents or board members of the American Association for Clinical Chemistry. Members were invited to review the company's proprietary technologies and advise on the integration into clinical practice.
Nielsen, Brenner and Janda also used the Kerr approach for implementing the DNA encoding In the latest period of time there were important advancements in DNA sequencing. The next generation techniques make it possible to sequence large number of samples in parallel that is very important in screening of DNA encoded libraries. There was another innovation that contributed to the success of DNA encoding. In 2000, Halpin and Harbury omitted the solid support in the split-mix synthesis of the DNA encoded combinatorial libraries and replaced it by the encoding DNA oligomers. In solid phase split and pool synthesis, the number of components of libraries can't exceed the number of the beads of the support. By the novel approach of the authors, this restraint was eliminated and made it possible to prepare new compounds in practically unlimited number. The Danish company Nuevolution, for example, synthesized a DNA encoded library containing 40 trillion! components The DNA encoded libraries are soluble and s posit ible to apply the efficient affinity binding in screening. Some authors use the acronym DEL for DNA encoded combinatorial libraries, while others use DECL. The latter seems better since in this name, the combinatorial nature of these libraries is clearly expressed. Sev Sal types of DNA encoded combinatorial libraries had been introduced and described in the first decade of the present millennium. These libraries are very successfully applied in drug research.
Sources: en.wikipedia.org
==== Other members ==== Octian Porupo (オクト星人ポルポ, Okuto Seijin Porupo): An octopus-themed member of S.P.D., and Ban's former instructor from Planet Octo, who feels his student should be removed from S.P.D. due to his recklessness. Porupo is voiced by Issei Futamata (二又 一成, Futamata Issei). Horusian Numa-O (ホルス星人ヌマ・O, Numa Ō): The professional avian supreme commander of S.P.D. from Planet Horus. Numa-O is voiced by Kazuhiko Kishino (岸野 一彦, Kishino Kazuhiko). Tortorian Buntar (トート星人ブンター, Tōto Seijin Buntā): An ape-themed member of S.P.D., and old friend of Kruger's, from Planet Torto, who owns a mechanical dog named Clarence K-9 (クラレンスK9, Kurarensu Kē Nain) and trains the Dekarangers to assume their S.W.A.T. Modes. Buntar is voiced by Naoki Kusumi (楠見 尚己, Kusumi Naoki). Lumierian Lisa Teagle (リュミエル星人リサ・ティーゲル, Ryumieru Seijin Risa Tīgeru): The chief of the Tokkyou Division's first squad from Planet Lumiere, and Tetsu's mentor, who believes that the perfect officer must be passionless to be efficient. Additionally, using her own Bracerottle, she can transform into the silver-colored Deka Bright (デカブライト, Deka Buraito). After coming to Earth, she initially intended to take Tetsu back for straying from her teachings, but decides against that after seeing him fight, realizing that passion can be a positive trait for an officer. Lisa Teagle is portrayed by Mie Nanamori (七森 美江, Nanamori Mie).
Concurrently, the Bureau of Longitude Studies and the Observatory were undertaking a comprehensive review of his extensive barometric and astronomical measurements. Furthermore, artists had been commissioned to commence the replication of his botanical sketches and illustrations of ancient Indian monuments. At this time, Napoleon Bonaparte was the only person in Europe with greater fame than Humboldt. Their sole meeting was unsuccessful, with Napoleon responding coldly, possibly viewing Humboldt as a politically suspect foreigner. Despite this, Napoleon granted a pension to Bonpland but later attempted to expel Humboldt from Paris on suspicion of espionage. Paris, despite political changes since Humboldt’s departure, was now the leading center of science, offering exceptional resources and collaborators. Humboldt chose to remain, preferring Paris’s intellectual and social environment over Berlin, which he considered unappealing. He immersed himself in work, organizing his extensive collections and distributing specimens to various institutions. Bonpland kept the most complete set of plant specimens, with other collections sent to major European botanical gardens. Humboldt’s dedication to processing and publishing his scientific findings required several years of intense effort. During their American expedition, Alexander von Humboldt and Aimé Bonpland encountered numerous challenges and hardships, many of which were described in Humboldt’s Voyage aux régions équinoxiales du Nouveau Continent and related works.
== Interactions == Co-administration with erythromycin, ketoconazole, azithromycin, fluoxetine, or cimetidine resulted in elevated blood plasma concentrations of desloratadine and its metabolite 3-hydroxydesloratadine in studies. However, no clinically relevant changes were observed.
== Environmental record == Since 2000, the company has implemented more than 4,000 greenhouse gas reduction projects. Pfizer has inherited Wyeth's liabilities in the American Cyanamid site in Bridgewater Township, New Jersey, a highly toxic EPA Superfund site. Pfizer has since attempted to remediate this land in order to clean and develop it for future profits and potential public uses. The Sierra Club and the Edison Wetlands Association have opposed the cleanup plan, arguing that the area is subject to flooding, which could cause pollutants to leach. The EPA considers the plan the most reasonable from considerations of safety and cost-effectiveness, arguing that an alternative plan involving trucking contaminated soil off site could expose cleanup workers. The EPA's position is backed by the environmental watchdog group CRISIS. In June 2002, a chemical explosion at the Groton plant injured seven people and caused the evacuation of more than 100 homes in the surrounding area.
Sources: en.wikipedia.org
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.
The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.
Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.